Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.

@article{McKay2015DocetaxelBA,
  title={Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.},
  author={Rana R. McKay and Kathryn P. Gray and Julia H Hayes and Glenn J. Bubley and Jonathan E Rosenberg and Arif Hussain and Philip W. Kantoff and M E Taplin},
  journal={Cancer},
  year={2015},
  volume={121 15},
  pages={2603-11}
}
BACKGROUND Patients with biochemical disease recurrence (BCR) after definitive treatment for prostate cancer comprise a heterogeneous population for whom standard therapy options are lacking. The purpose of the current trial was to evaluate the feasibility, toxicity, and efficacy of early multimodality systemic therapy in men with BCR. METHODS Eligible… CONTINUE READING